https://acyltransferase-recept....or.com/index.php/cd7
Methods We evaluated delayed therapy with subcutaneous rhu-pGSN initiated 3 to 6 days after intra-nasal viral challenge in a mouse style of influenza A/PR/8/34. Outcomes Rhu-pGSN administered beginning on time 3 or day 6 increased survival (12-day survival 62 per cent vs 39 %, pGSN vs vehicle; p less then 0.00001, summary of 18 trials), reduced morbidity, and reduced pro-inflammatory gene expression. Conclusions Rhu-pGSN improves results in a highly
Like
Comment
Share
